PhaseBio Pharmaceuticals Inc. (PHAS) and OPKO Health Inc. (NASDAQ:OPK) Comparison side by side

PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and OPKO Health Inc. (NASDAQ:OPK), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PhaseBio Pharmaceuticals Inc. 8 247.05 N/A -1.09 0.00
OPKO Health Inc. 3 1.33 N/A -0.27 0.00

In table 1 we can see PhaseBio Pharmaceuticals Inc. and OPKO Health Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows PhaseBio Pharmaceuticals Inc. and OPKO Health Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
PhaseBio Pharmaceuticals Inc. 0.00% 0% 0%
OPKO Health Inc. 0.00% -10.7% -7.6%


PhaseBio Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 13.7 and 13.7 respectively. The Current Ratio and Quick Ratio of its competitor OPKO Health Inc. are 1.1 and 1 respectively. PhaseBio Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to OPKO Health Inc.

Insider and Institutional Ownership

Institutional investors owned 56.9% of PhaseBio Pharmaceuticals Inc. shares and 23.2% of OPKO Health Inc. shares. About 0.1% of PhaseBio Pharmaceuticals Inc.’s share are owned by insiders. Comparatively, insiders own roughly 5.4% of OPKO Health Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PhaseBio Pharmaceuticals Inc. -12.19% -11.99% 290.3% 132.93% 0% 277.67%
OPKO Health Inc. -0.48% -15.45% -24.91% -32.69% -35.4% -30.9%

For the past year PhaseBio Pharmaceuticals Inc. has 277.67% stronger performance while OPKO Health Inc. has -30.9% weaker performance.


On 6 of the 7 factors PhaseBio Pharmaceuticals Inc. beats OPKO Health Inc.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.